YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Shares of electric vehicle (EV) giant Tesla TSLA have plunged nearly 18% over the past week, marking their worst weekly slump since 2022 and continuing the trend seen over the past several quarters. This follows the stock's slip of nearly…
Electric vehicle ("EV") giant Tesla TSLA has delivered a record-breaking 480,126 vehicles in the second quarter of 2026, crushing Wall Street estimates of around 406,000 and marking a 25% year-over-year improvement. Yet, instead of celebra…
Alibaba BABA shares surged to their highest price in nearly four years after unveiling renewed plans to boost artificial intelligence (AI) spending beyond its original $50 billion-plus commitment, per a Bloomberg article, as quoted on Yaho…
Tesla TSLA reported dismal first-quarter 2025 results, missing estimates for earnings and revenues. The company posted its biggest decline in quarterly revenues in more than a decade, as CEO Elon Musk’s increasingly polarizing political ac…
[tesla supercharger at night] Anski Elon Musk’s Tesla (NASDAQ:TSLA [https://seekingalpha.com/symbol/TSLA]) is set to report its latest quarterly results after the closing bell on Wednesday, and the ripple effects could extend well beyond t…
Electric carmaker Tesla TSLA is scheduled to report results for the second quarter of 2025 on July 23 after market close. Tesla has gained about 56% over the past three months, outperforming the industry’s growth of 28.8%. The solid trend…
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tesla, Inc. (TSLA) : Free Stock Analysis Report Consumer Discretionary Select Sector…
On Tuesday, Target Corporation (NYSE:TGT) outlined a strategic plan to drive over $15 billion in sales growth by 2030, focusing on style, innovation, and value. Starting in 2025, Target plans to launch a multi-year initiative to expand hig…
Wynn Resorts' Q3 Performance Misses Expectations Amid Strategic Investments Wynn Resorts, Limited (NASDAQ:WYNN) shares are trading lower on Tuesday after the company reported worse-than-expected third-quarter EPS and revenues. On Monday, t…
BlackRock In Talks To Deepen Ties With Mukesh Ambani For Private Credit Venture BlackRock, Inc. (NYSE:BLK) reportedly plans to establish a private credit venture with Indian billionaire and the richest Asian Mukesh Ambani’sJio Financial Se…
BlackRock's Steady Climb: Q3 Earnings Beat Projections, Assets Under Management Soars To $11.5T Investment giant BlackRock, Inc. (NYSE:BLK) shares are trading higher after the company reported third-quarter results. Revenue growth of 15% Y…
BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experie…
Life sciences industry veteran brings more than 25 years of financial and operational experience BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, today announc…
Life sciences industry veteran brings more than 25 years of financial and operational experience BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, today announc…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM,…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM,…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM,…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM,…
WALTHAM, Mass. and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar") (NASDAQ: NITE) today announced that both leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and G…
NEW YORK, April 17, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of WageWorks, Inc. (NYSE:WAG…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM,…
NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating whether the sale of Nightstar Therapeutics plc (“Nightstar” or the “Company”) (NASDAQ: NITE) to Biogen Inc. (“B…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM,…
Biogen to acquire Nightstar for US$ 25.50 per share in cash Transaction expected to be completed by mid-year 2019 WALTHAM, Mass. and LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar") (NASDAQ: NITE), a clin…
Phase 2/3 Expansion Study to Include No-Sham Control Arm in Alignment with FDA Draft Guidance on Development of Gene Therapy Products for Retinal Disorders Preliminary Efficacy Data from Phase 2/3 Expansion Study Expected in Mid-2019 WALTH…
WALTHAM, Mass. and LONDON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company will p…
NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Corcept Therapeuti…
WALTHAM, Mass. and LONDON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company plans…
WALTHAM, Mass. and LONDON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the closing of its unde…
WALTHAM, Mass. and LONDON, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company plans…
WALTHAM, Mass. and LONDON, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the pricing of an unde…
WALTHAM, Mass. and LONDON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that it has commenced…
NSR-RPGR data presented at EURETINA 2018 Congress demonstrated proof of concept with durable dose-related improvements seen as early as month 1 across multiple microperimetry analyses Preliminary efficacy signals observed in 3/3 patients i…
WALTHAM, Mass. and LONDON, United Kingdom, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that t…
Regenerative Medicine Advanced Therapy (RMAT) Designation received in June 2018 for NSR-REP1 in Choroideremia Preliminary data from Phase 1/2 XIRIUS trial for X-Linked Retinitis Pigmentosa expected at EURETINA 2018 in Vienna, Austria in Se…
First gene therapy RMAT designation for an inherited retinal diseaseSTAR Phase 3 registrational trial ongoing and FDA interactions plannedRMAT designation enables closer and more frequent multidisciplinary interaction with FDA with all of…